Medicine to eradicate HIV:

by Enrique Gutierrez

Vanadium complex have virucidal activity against HIV and Glyburide can inhibits pyroptosis( self destruction ) of HIV infected CD4+ cells. Combination of these drug can potentiate HAART drugs.
St. Cloud, FL United States Biotech Infectious Disease Drug Development

All Team Company Innovation Details Supporters Comments Updates

About our project

The problem we solve:
Current HAART therapy reduces the viral load to undetectable level. But virus persists as provirion in CD4+ and other infected T lymphocytes. Currently there is no drug that targets this provirion. Also low CD4 cells and CD4/CD8 cell ratios persists in spite of treatment causing increased infection, malignancy and non-aids morbidity and mortality.
About our solution:
This treatment raises CD4 T cells and normalizes CD4/CD8 T cell ratios. We want to start feasibility study to show if these drugs are effective in small group of patients. We need to come up with a chemical entity and we have already spoken with a team of scientist who have agreed to work on your project. In our small observation in few patients we have found vanadium compounds are highly active against HIV and we would like to develop and start a new clinical trial to test our product.
Progress to date:

We did observational studies in small pool of 13 subjects  and they have shown increase in CD4+ cells count more quickly in subjects who are taking vanadium complexes than patients who are not taking. Not only cells have improved but also the CD4/CD8 T cell ratio is improved more quickly than historic cohorts. These effects resulted in reduced frequency of other bacterial,fungal and viral infections. Patients are able to lead normal life with less visits to emergency hospital visits. Please see our video for discussion on this topic.


About Our Team

Creator: Enrique Gutierrez
Location: Florida
Education: Tulane University, USA & Universidad Centr
Bio: Board Certified Physician practicing in Kissimmee for over 20 years. Specialize in treating patient with HIV. He completed a specialty fellowship in allergy and immunology and Endocrinology at the prestigious Tulane University. Tulane University is one of the top endocrinology programs in the nation attending Tulane gave him the opportunity to train under Nobel Prize winning academicians. During his time there he conducted and published ground breaking research in the area of neuro endocrinology and neuro immunology. He has led many pharmaceutical clinical trials and collaborated in developing new drugs with different pharmaceutical companies . His research is primarily focused on vanadium compound and micronized glyburide for the treatment of HIV.
Hospital Affiliation: Epigene Channel
Title: Founder & President
Advanced Degree(s): MD

About Team Members

Dawood Subhani
Dr., M.B.B.S., C.T.D.M
Biography: Dr.Dawood is a Physician and Clinical researcher. He has experience in managing several investigator-initiated studies and held research job positions at USC, UCSC, VA SFO, collaborated on many research/clinical trials with reputed universities like Stanford, Harvard etc., expert in managing day- to-day clinical trial activities, and providing support for regulatory filings.
Title: Dr.
Advanced Degree(s): M.B.B.S., C.T.D.M
LinkedIn: www.linkedin.com/in/dawood-subhani-03aa337

About Our Company

Epigene Channel LLC
Location: 1914 Sir Lancelot Circle
St. Cloud, Florida 34772
Product Stage: Prototype/MVP
YTD Sales: Working on it
Employees: 1-2

Innovation Details

Intellectual Property Summary

Compositions and related methods for treating and preventing viral and retroviral infections 
WO 2015148684 A3

ZUSAMMENFASSUNG

Disclosed are pharmaceutical compositions and related methods for treating a subject with a viral or retroviral infection. The disclosed compositions and methods comprise and utilize an effective amount of one or more vanadium-containing compounds and an effective amount of one or more sulfonylureas. In certain embodiments, the viral infection is human immunodeficiency virus (HIV) and the compositions and methods improve one or more immunologic cellular parameters, such as viral load, CD4 counts and CD4/CD8 lymphocyte cell ratios in a subject. Also disclosed are methods of improving one or more immunologic cellular parameters that are associated with viral infections such as HIV in a subject, including viral load, CD4 counts and CD4/CD8 lymphocyte cell ratios.

Patent Link
http://www.google.ch/patents/WO2015148684A3?cl=en

Clinical Information

Patient observation over a period of 5 years was noted and documented. Lab improvement in CD4 T cell count, CD8 T cell count and CD4/CD8 cell  ration is consistent, varifiable and objective measurement. HIV RNA titer is not only reduces to undetectable levels but also remains undetectable for a long period. As these patients are already on HAARTherapy viral titer is already low except in non compliant patient and in patients who develop adverse effects and become non compliant. 

Regulatory Status

We are in the process of filing initial IND application.

How we will use the funds raised

1. Manufacture Vanadyl Sulfate according to cGMP specification.

2. Contract CRO to do stability and microbial testing as per the requirement.

3. Use IRB services and Stasticians and Data Monitoring services.

4. Conduct clinical trial in our facility 

 

Thank You

Millions of HIV infected patients are carrying dormant virus. If subjects discontinue the drugs then virus comes back causing AIDS. Please see the video for elaborate discussion.

Supporters

Comments

Login to post your comment!
Click here to Login

Updates

    No updates found .

$ 0

pledged of $ 1,000,000 goal

  • 39 Days left

4

Interest
Score

0

Adoption
Score

Enrique Gutierrez
Founder & President
Tulane University, USA & Universidad Centr

Proflle
Contact Me


Rewards All contributions are tax-deductible.